BLUE MARCH - Colorectal Cancer Awareness Month.
28 February 2023
Join us for a deep dive experience into our incredible colon!
Colorectal cancer (CRC) is the third most common cancer in the world,1 with 1 in 4 people diagnosed when the disease has already spread to other parts of the body (metastasised).2
It is also the 2nd most deadly cancer in the world with over 930 000 deaths in 20202.
So what can we do?
Once again this year, the Pierre Fabre Group is committed to raising public awareness of CRC prevention and screening, and to supporting the actions carried out by patient associations through the Blue March campaign "The wonderful colon".
The objective of our action?
To invite the general public to take part in an immersive experience to discover this wonderful and not well-known organ and how to take care of it.
Through a deliberately positive and playful approach, the user will be able to learn more about how this organ works, why and how to take care of it, before tackling the subject of colorectal cancer, from its detection to its treatment.
It is important to raise awareness around reducing the risk and early detection of tumors as early diagnosis of CRC results in better outcomes than if diagnosed after the disease has metastasized.3
There are a range of everyday actions and activities that can help reduce the risk of colorectal cancer.4 Whatever the habits, lifestyle choices or individuality, everyone can do something to participate in CRC prevention and screening.
To learn more and take part in the diving experience, visit www.thewonderfulcolon.com/en
Our goal is still the same,
Every time we care for a single person, we make the whole world better.
CRC Facts and Figures,
- The Global Cancer Observatory, 2020. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars. Accessed January 2022.
- Van Cutsem E, et al. Ann Oncol. 2014;25(Suppl 3):iii1–iii9.
- Gunter MJ, et al. Ann Oncol. 2019;doi: 10.1093/annonc/mdz044.
- Kerr J, et al. Lancet Oncol. 2017; 18(8):e457–71. doi: 10.1016/S1470-2045(17)30411-4.